A.R.T. Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

A.R.T. Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-26,356	Closed	-$14K	–	1267
2019 Q4	$14K	Sell	26,356 -10,264	-28%	-$24.9K	﹤0.01%	1288
2019 Q3	$140K	Buy	+36,620	New	+$132K	0.01%	1234
2019 Q1	–	Sell	-8,956	Closed	-$35K	–	1782
2018 Q4	$35K	Buy	8,956 +3,549	+66%	+$45.4K	﹤0.01%	1232
2018 Q3	$106K	Buy	+5,407	New	+$137K	﹤0.01%	1269
2018 Q2	–	Sell	-3,852	Closed	-$142K	–	1932
2018 Q1	$142K	Sell	3,852 -7,981	-67%	-$525K	0.01%	1324
2017 Q4	$934K	Buy	+11,833	New	+$876K	0.04%	647

A.R.T. Advisors's MLNT Position: Q1 2020 in Review

A.R.T. Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 26,356 shares — an estimated $14K sold.

A.R.T. Advisors first reported a position in MLNT in Q4 2017 and held it in 6 quarters. The position peaked at $934K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

A.R.T. Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 26,356 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $14K.
A.R.T. Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
A.R.T. Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $934K in Q4 2017.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.